[MO-91] Comparison of Clinical Outcome between Patient with and without Hemodialysis after Endovascular Treatment with Heparin-Bonded Covered Stent.
Background: In recent years, Heparin-Bonded Covered Stent; Viabahn (W. L. Gore & Associates, Flagstaff, Ariz) improved the patency of femoro-popliteal lesions. However, the outcome of patients on hemodialysis (HD) is still unknown. The objective of this study is to assess mid-term clinical outcome of endovascular treatment with Viabahn in patients on HD.
Methods: We included patients treated with Viabahn from January, 2017 to April, 2018 in our institution, divided them into two groups; on-HD group and non-HD group, and retrospectively analyzed. The strategy of treatment was left to the discretion of the attending physician. Primary endpoints were primary patency defined as no evidence of significant restenosis, and freedom from clinical driven target lesion revascularization. Secondary endpoints were major adverse cardiac event (MACE), major adverse limb event (MALE), graft thrombosis and graft infection.
Results: 73 patients (54 patients non-HD and 19 on-HD) and 95 lesions (72 non-HD lesions and 23 on-HD lesions) were analyzed. Patients baseline characteristics ware almost well balanced between two groups, however there were more male patients in on-HD group (48.2% vs 80.0%, p=0.02). TASCⅡ class C or D lesion were included 87.5% and 91.3% (p=0.61), lesion length were 274±80mm and 268±86mm (p=0.76), and severe calcified lesion (defined as PACCS classification 3 and 4) were 33.3% and 73.9% (p=0.0006) respectively.
Mean follow-up period was 287.1 days and 263.7 days (p=0.47). Significant restenosis was occurred in 8 and 3 lesions, and 2 and 2 patients developed stent graft occlusion. Primary patency rate and assisted primary patency rate were not significantly different (p=0.80, p=0.60).
Conclusions: Heparin-banded stent graft might be effective for patients on hemodialysis as well as patients without hemodialysis in our cohort.
Methods: We included patients treated with Viabahn from January, 2017 to April, 2018 in our institution, divided them into two groups; on-HD group and non-HD group, and retrospectively analyzed. The strategy of treatment was left to the discretion of the attending physician. Primary endpoints were primary patency defined as no evidence of significant restenosis, and freedom from clinical driven target lesion revascularization. Secondary endpoints were major adverse cardiac event (MACE), major adverse limb event (MALE), graft thrombosis and graft infection.
Results: 73 patients (54 patients non-HD and 19 on-HD) and 95 lesions (72 non-HD lesions and 23 on-HD lesions) were analyzed. Patients baseline characteristics ware almost well balanced between two groups, however there were more male patients in on-HD group (48.2% vs 80.0%, p=0.02). TASCⅡ class C or D lesion were included 87.5% and 91.3% (p=0.61), lesion length were 274±80mm and 268±86mm (p=0.76), and severe calcified lesion (defined as PACCS classification 3 and 4) were 33.3% and 73.9% (p=0.0006) respectively.
Mean follow-up period was 287.1 days and 263.7 days (p=0.47). Significant restenosis was occurred in 8 and 3 lesions, and 2 and 2 patients developed stent graft occlusion. Primary patency rate and assisted primary patency rate were not significantly different (p=0.80, p=0.60).
Conclusions: Heparin-banded stent graft might be effective for patients on hemodialysis as well as patients without hemodialysis in our cohort.